Comparing SG&A Expenses: AbbVie Inc. vs Grifols, S.A. Trends and Insights

SG&A Expenses: AbbVie vs Grifols - A Decade of Trends

__timestampAbbVie Inc.Grifols, S.A.
Wednesday, January 1, 20147724000000660772000
Thursday, January 1, 20156387000000736435000
Friday, January 1, 20165855000000775266000
Sunday, January 1, 20176275000000860348000
Monday, January 1, 20187399000000814775000
Tuesday, January 1, 20196942000000942821000
Wednesday, January 1, 202011299000000985616000
Friday, January 1, 2021123490000001061508000
Saturday, January 1, 2022152600000001190423000
Sunday, January 1, 2023128720000001254234000
Monday, January 1, 202414752000000
Loading chart...

Infusing magic into the data realm

SG&A Expenses: A Tale of Two Companies

In the ever-evolving pharmaceutical industry, understanding the financial dynamics of major players is crucial. AbbVie Inc. and Grifols, S.A., two giants in the sector, have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses over the past decade.

AbbVie Inc.: A Steady Climb

From 2014 to 2023, AbbVie Inc. has seen a significant increase in SG&A expenses, peaking in 2022 with a 97% rise from 2014. This upward trajectory reflects the company's aggressive expansion and marketing strategies.

Grifols, S.A.: A Consistent Path

In contrast, Grifols, S.A. has maintained a more stable SG&A expense pattern, with a modest 90% increase over the same period. This consistency highlights Grifols' focus on operational efficiency and cost management.

These insights offer a glimpse into the strategic priorities of these pharmaceutical leaders, providing valuable lessons for investors and industry analysts alike.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025